References
- Nichols CR, Roth BJ, Williams SD, Gill I, Muggia FM, Stablein DM, et al. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10: 760–5
- Doehn C, Büttner H, Fornara P, Jocham D. Fatal basilar artery thrombosis after chemotherapy for testicular cancer. Urol Int 2000; 65: 43–5
- Lepidini G, Biancari F, D'Andrea V. Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Scand J Urol Nephrol 1997; 31: 221–2
- Schmidt J, Zenut M, De Marquilly F, Maciejewski C, Plagne R, Lavarenne J. Arterial thrombosis in a patient after chemotherapy (BEP protocol) for extra-gonadal dysgerminoma. Thérapie 1995; 50: 476–8
- Içli F, Karaoguz H, Dinçol D, Demirkazik A, Günel N, Karaoguz R, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587–93
- Illaramendi JJ, Gallego J. Cisplatin-based chemotherapy and acute cerebrovascular events. Lancet 1991; 338: 705
- Cheng, E, Berthold, DR, Moore, MJ, Duran, I. Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. Acta Oncol 2008, (in press).
- Grenader T, Shavit L, Ospovat I, Gutfeld O, Peretz T. Aortic occlusion in patients treated with Cisplatin-based chemotherapy. Mt Sinai J Med 2006; 73: 810–2
- Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765–70
- Scappaticci FA, Shillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232–9
- Weijl NI, Ruten MF, Zwinderman H, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 2000; 18: 2169–78
- Sgouros J, Maraveyas A. Excess premature (3-months) mortality in advanced pancreatic cancer could be related to fatal vascular thromoboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol 2008; 47: 337–46
- Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–53